



06-10-05

JFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/786,316
	Filing Date	February 25, 2004
	First Named Inventor	Bharat B. Aggarwal
	Art Unit	N/A
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	AO-CLFR:215US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): Return Receipt Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	FULBRIGHT & JAWORSKI L.L.P.		
Signature			
Printed name	Melissa W. Acosta, Ph.D.		
Date	June 9, 2005	Reg. No.	45,872

Transmittal	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 671534203 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: June 9, 2005	Signature:  Julie Erwin)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 671534203 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 9, 2005

Signature: Julie Erwin

(Julie Erwin)

Docket No.: AO-CLFR:215US  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Bharat B. Aggarwal

Application No.: 10/786,316

Filed: February 25, 2004

Art Unit: N/A

For: **INHIBITORS OF RECEPTOR ACTIVATOR  
OF NF-KB AND USES THEREOF**

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. AO-CLFR:215US.

Dated: June 9, 2005

Respectfully submitted,

By 

Melissa W. Acosta, Ph.D.

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

Fulbright Tower


1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)

Agent for Applicant



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				<b>Complete if Known</b>	
				Application Number	10/786,316
				Filing Date	February 25, 2004
				First Named Inventor	Bharat B. Aggarwal
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	AO-CLFR:215US

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-5,843,678	12-01-1998	Boyle	
	AB	US-6,017,729	01-25-2000	Anderson et al.	
	AC	US-6,271,349	08-07-2001	Dougall et al.	
	AD	US-20030013170	01-16-2003	Aggarwal et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	BA	WO-2002092623	11-21-2002	Aggarwal et al.	
	BB	WO-199958674	11-18-1999	Anderson et al.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Akiba et al, "CD27, a Member of the Tumor Necrosis Factor Receptor Superfamily, Activates NF-κB and Stress-activated Protein Kinase/c-Jun N-terminal Kinase via TRAF2, TRAF5 and NF-κB-Inducing Kinase," The Journal of Biological Chemistry Vol. 273, No. 21, May 22, 1998, pgs 133353 - 13358.	
	CB	Bharti et al, "Evidence that areceptor Activator of Nuclear Factor (NF)-κB Ligand Can Supress Cell Proliferation and Induce Apoptosis through Activation of a NF-κB-Independent and TRAF6-Dependent Mechanism," The Journal of Biological Chemistry Vol. 279, No. 7, February 13, 2004, pgs 6065 - 6076.	
	CC	Caldwell, J. "The Importance of Drug Metabolism Studies for Efficient Drug Discovery and Development," Xenobiotic Metabolism and Disposition Vol. 11 no. 1, 1996, pgs 119 - 126.	
	CD	Darnay et al, "Activation of NF-κB by RANK Requires Tumor Necrosis Factor Receptor-Associated Factor (TRAF) 6 and NF-κB-inducing Kinase: Identification of a Novel TRAF6 Interaction Motif," The Journal of Biological Chemistry Vol. 274, No. 12, March 19, 1999, pgs 7724 - 7731.	
	CE	Darnay et al, "Characterization of the Intracellular Domain of Receptor Activator of NF-κB (RANK)," The Journal of Biological Chemistry Vol. 273, no. 32, August 7, 1998, pgs 20551 - 20555.	
	CF	Futaki et al, "Arginie-Rich Peptides: An Abundant Source of Membrane-Permeable Peptides Having Potential As Carriers for Intracellular Protein Delivery," The journal of Biological Chemistry Vol. 276, No. 8, February 23, 2001, pgs 5836 - 5840.	
	CG	Galibert et al, "The Involvement of Multiple Tumor Necrosis Factor Receptor (TNFR) - associated Factors in the Signaling Mechanisms of Receptor Activator of NF-κB, a Member of the TNFR Superfamily," The Journal of Biological Chemistry Vol. 273, No. 51, december 18, 1998, pgs 34120 - 34127.	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/786,316
				Filing Date	February 25, 2004
				First Named Inventor	Bharat B. Aggarwal
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	AO-CLFR:215US

CH	Gravallese et al., "The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption," Arthritis Res., Vol. 3, 2000, pgs. 6-12.
CI	Horwell, D.C., "The "Peptoid" Approach to the Design of Non-Peptide, Small Molecule Agonists and Antagonists of Neuropeptides," Trends in Biotechnol Vol 13, 1995, pgs 132 - 134.
CJ	Hsu et al, "Tumor Necrosis Factor Receptor Family Member RANK mediates Osteoclast Differentiation and Activation Induced by Osteoprotegerin Ligand," Proc. Natl. Acad. Sci USA Vol. 96, March 1999, pgs 3540 - 3545.
CK	Kim et al, "Receptor Activator of NF- $\kappa$ B Recruits Multiple TRF Family Adaptors and Activates c-Jun N-terminal Kinase," FEBS Letts Vol. 443, 1999, pgs 297 - 302.
CL	Lindgren et al., "Cell-penetrating peptides," TIPS, Vol. 21, 2000, pgs. 99-103.
CM	McWhirter et al, "Crystallographic Analysis of CD40 Recognition and Signaling by Human TRAF2," Proc Natl. Acad. Sci Vol. 96, July 1999, pgs 8408 - 8413.
CN	Oyajobi et al., "Therapeutic Efficacy of a Soluble Receptor Activator of Nuclear Factor $\kappa$ B-IgG Fc Fusion Protein in Suppressing Bone Resorption and Hypercalcemia in a Model of Humoral Hypercalcemia of Malignancy," Cancer Research, Vol. 61, 2001, pgs. 2572-2578.
CO	Park et al, "Structural Basis for Self-Association and Receptor Recognition of Human TRAF2," Nature Vol. 398, April 8, 1999, pgs 533 - 538.
CP	Pullen et al, "CD40 Signaling through Tumor Necrosis Factor Receptor-Associated Factors (TRAFs)," J. Biol. Chem Vol. 274 No. 20, 1999, pgs 14246 - 14254.
CQ	Saragovi et al, "Loops and Secondary Structure Mimetics: Development and Applications in Basic Science and Rational Drug Design," Biotechnology Vol. 10, July 1992, pgs 773 - 778.
CR	Shevde et al, "Estrogens Suppress RANK Ligand-Induced Osteoclast Differentiation Via a Stromal Cell Independent Mechanism Involving c-Jun Repression," PNAS Vol. 97, No. 14, July 5, 2000, pgs 7829 - 7834.
CS	Shin et al., "Identification of a negative regulator of tumor necrosis factor receptor-associated factor 6," Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biol, 2001.
CT	Takayanagi et al., "T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN- $\gamma$ ," Nature, 408, 2000.
CU	Werneburg et al., "Molecular Characterization of CD40 Signaling Intermediates," J. Biol. Chem., Vol. 276, No. 46, 2001, pgs. 43334-43342.
CV	Wesche et al, "IRAK-M is a Novel Member of the Pell/Interleukin-1 Receptor-associated Kinase (IRAK) Family," The Journal of Biological Chemistry Vol. 274, No. 27, July 2, 1999, pgs 19403 - 19410.
CW	Wexler et al, "Rationale for the Chemical Development of Angiotensin II Receptor Antagonists," Am. J. Hypertens Vol. 5, 1992, pgs 209S - 220S.
CX	Wong et al, "The TRAF Family of Signal Transducers Mediates NF- $\kappa$ B Activation by the TRANCE Receptor," The Journal of Biological Chemistry, Vol. 273, No. 43, October 23, 1998, pgs 28355 - 28359.
CY	Yasuda et al., "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG); a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro," Endocrinology, Vol. 139, No. 3, 1998, pgs. 1329-1337.
CZ	Ye et al, "Distinct Molecular Mechanism for Initiating TRAF6 Signalling," Nature Vol. 418, July 25, 2002, pgs. 443 - 447.
CA1	Yeh et al, "From Consensus Sequence Peptide to High Affinity Ligand, a "Library Scan" Strategy," The Journal of Biological Chemistry Vol. 276, No. 15, April 13, 2001, pgs 12235 - 12240.
CB1	Zhang et al., "Tumor necrosis factor- $\alpha$ (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways," J. Biol. Chem., Vol. 276,

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/786,316
Filing Date	February 25, 2004
First Named Inventor	Bharat B. Aggarwal
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	AO-CLFR:215US

Sheet	3	of	2
-------	---	----	---

No. 1, 2001, pgs. 563-568.
----------------------------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Application No. (if known): 10/786,316

Attorney Docket No.: AO-CLFR:215US



## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 671534203 US in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on June 9, 2005  
Date



Signature

Julie Erwin

Typed or printed name of person signing Certificate

Registration Number, if applicable

(713) 651-5187  
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (3 pages)  
Information Disclosure Statement  
Transmittal